REGENXBIO Inc (RGNX) Stock Price

9.97 ▲ +0.02 (+0.20%)
Open: 10.13 Vol: 2.29M Day's range: 9.86 - 10.98 Jun 24, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
RGNX Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 9.98▲ 10.05▼ 10.18▼ 8.94▲ 7.50▲
MA10 9.99▼ 10.28▼ 10.26▼ 7.78▲ 7.80▲
MA20 10.02▼ 10.29▼ 9.83▲ 7.21▲ 8.15▲
MA50 10.21▼ 9.40▲ 8.45▲ 8.00▲ 10.00▼
MA100 10.31▼ 8.31▲ 7.40▲ 8.44▲ 9.53▲
MA200 9.93▲ 7.34▲ 6.95▲ 10.34▼ 14.31▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.009▲ -0.123▼ -0.084▼ 0.475▲ 0.098▲
RSI 38.580▼ 49.968▼ 59.408▲ 70.961▲ 54.041▲
STOCH 45.298     10.930▼ 42.698     79.261     31.384    
WILL %R -48.571     -89.286▼ -54.348     -19.804▲ -23.559▲
CCI -102.976▼ -93.661     -41.671     169.065▲ 93.920    
Latest Filters Detected On RGNX
▲ RSI $RGNX RSI(14) Crossed Above 70 Set Alert
▲ BREAK $RGNX Price Breaks 20 Days High Set Alert
▲ BREAK $RGNX Price Breaks 10 Days High Set Alert
REGENXBIO Inc News
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
Wednesday, June 24, 2026 04:33 AM
REGENXBIO Inc. (Nasdaq: RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. This ...
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
Monday, June 22, 2026 06:14 AM
REGENXBIO Inc. (Nasdaq: RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of NAVSUNLI™ ...
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success
Thursday, May 14, 2026 12:24 PM
・REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, raising cash concerns. ・Cash, cash equivalents, and ...
RGNX historical stock data
date open high low close volume
24/06/26 10.13 10.98 9.86 9.97 2,290,133
23/06/26 9.07 10.34 9.06 9.95 2,955,570
22/06/26 8.50 9.65 7.82 9.07 8,992,225
18/06/26 8.20 8.575 7.78 7.80 2,540,682
17/06/26 7.20 8.72 7.18 7.90 4,773,280
16/06/26 7.07 7.13 6.59 6.93 886,929
15/06/26 6.79 7.11 6.76 7.07 1,630,050
12/06/26 6.36 6.67 6.3207 6.66 901,432
11/06/26 6.07 6.315 5.88 6.28 1,384,692
10/06/26 6.33 6.51 6.09 6.13 821,417
Quote Details
52wk Low:5.46
52wk High:16.19
Vol:2.29M
Avg Vol(3m):29.4M
1Y Chng:+14.86%
1M Chng:-2.64%
Add to Watch List
More Information
Index US Composite
Market Cap. 555.23M